Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors

NCT05419375 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05419375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05419375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 22, 2022
Completion date
September 3, 2025
Enrollment
470 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors